Greenberg Audrey
Known title: DirectorCIK: 0001871975
Associated companies
this person other insiders at ADAMZ
Transaction History
| ADAMZ | ▲ Buy | Grant | 11,953 | $0 | 6/13/2023 | View on chart |
| ADAMZ | ▲ Buy | Grant | 38,586 | $0 | 6/6/2022 | View on chart |
| ADAMZ | ▲ Buy | Grant | 11,953 | $0 | 6/13/2023 | View on chart |
| ADAMZ | ▲ Buy | Grant | 38,586 | $0 | 6/6/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Adamas Trust ADAMZ Added to Navellier's Growth Momentum Checklist
Adamas Trust's Series G preferred shares attracted attention this week after being included on Navellier's growth momentum checklist, a market analysis service that tracks stocks demonstrating upward technical momentum. The stock is currently trading with high beta characteristics and recently touched its 200-day moving average while holding above a support level at $18.59. With a trailing P/E of 4.3, the shares have traded within a 52-week range of $6.45 to $10.36, and the current RSI reading of 46 suggests neutral momentum without extreme overbought or oversold conditions. This checklist inclusion represents routine market analysis coverage rather than a material corporate development for the preferred stock.
Adamas Trust ADAMZ Added to Navellier's Growth Momentum Checklist. Adamas Trust's Series G preferred shares attracted attention this week after being included on Navellier's growth momentum checklist, a market analysis service that tracks stocks demonstrating upward technical momentum. The stock is currently trading with high beta characteristics and recently touched its 200-day moving average while holding above a support level at $18.59. With a trailing P/E of 4.3, the shares have traded within a 52-week range of $6.45 to $10.36, and the current RSI reading of 46 suggests neutral momentum without extreme overbought or oversold conditions. This checklist inclusion represents routine market analysis coverage rather than a material corporate development for the preferred stock.